Literature DB >> 20927504

Designer lymphocytes to fight cancer: a helping hand from modern molecular biology.

Rolf Kiessling1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20927504     DOI： 10.1007/s00109-010-0682-6

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  12 in total

1.  Inducing autoimmune disease to treat cancer.

Authors:  D M Pardoll
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

2.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

3.  Precursor frequency of antigen-specific T cells: effects of sensitization in vivo and in vitro.

Authors:  D Ford; D Burger
Journal:  Cell Immunol       Date:  1983-07-15       Impact factor: 4.868

4.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.

Authors:  C L Bennett; J Christie; F Ramsdell; M E Brunkow; P J Ferguson; L Whitesell; T E Kelly; F T Saulsbury; P F Chance; H D Ochs
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

Review 5.  Prostate cancer as a model for tumour immunotherapy.

Authors:  Charles G Drake
Journal:  Nat Rev Immunol       Date:  2010-08       Impact factor: 53.106

6.  Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes.

Authors:  Peter Meyerhuber; Heinke Conrad; Lilian Stärck; Matthias Leisegang; Dirk H Busch; Wolfgang Uckert; Helga Bernhard
Journal:  J Mol Med (Berl)       Date:  2010-08-11       Impact factor: 4.599

7.  JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome.

Authors:  T A Chatila; F Blaeser; N Ho; H M Lederman; C Voulgaropoulos; C Helms; A M Bowcock
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

8.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Authors:  Laura A Johnson; Richard A Morgan; Mark E Dudley; Lydie Cassard; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Richard M Sherry; John R Wunderlich; Chyi-Chia R Lee; Nicholas P Restifo; Susan L Schwarz; Alexandria P Cogdill; Rachel J Bishop; Hung Kim; Carmen C Brewer; Susan F Rudy; Carter VanWaes; Jeremy L Davis; Aarti Mathur; Robert T Ripley; Debbie A Nathan; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-18       Impact factor: 22.113

9.  CTLs directed against HER2 specifically cross-react with HER3 and HER4.

Authors:  Heinke Conrad; Kerstin Gebhard; Holger Krönig; Julia Neudorfer; Dirk H Busch; Christian Peschel; Helga Bernhard
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

10.  Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.

Authors:  Helga Bernhard; Julia Neudorfer; Kerstin Gebhard; Heinke Conrad; Christine Hermann; Jörg Nährig; Falko Fend; Wolfgang Weber; Dirk H Busch; Christian Peschel
Journal:  Cancer Immunol Immunother       Date:  2007-07-24       Impact factor: 6.968
View more
  1 in total

1.  The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis.

Authors:  Xuejing Shao; Yujia Liu; Yangling Li; Miao Xian; Qian Zhou; Bo Yang; Meidan Ying; Qiaojun He
Journal:  Sci Rep       Date:  2016-04-14       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.